August M
For decades, men have had limited options when it comes to birth control, with little innovation since the late 20th century.
Now, new scientific advances suggest that could soon change, offering alternatives that move beyond traditional methods.
Researchers are exploring a new approach that targets sperm production directly, raising hopes for a safe and reversible male contraceptive.
Current options remain largely confined to condoms and vasectomies, but growing demand and ongoing trials indicate that more choices could be on the horizon, reports ScienceAlert.
Breakthrough approach
According to ScienceAlert, scientists at Cornell University have developed a drug that interrupts sperm formation at a key stage inside the testes.
The method focuses on meiosis, a process in which cells divide to produce sperm with the correct number of chromosomes.
“We’re practically the only group that’s pushing the idea that contraception targets in the testis are a feasible way to stop sperm production,” says geneticist Paula Cohen from the Cornell Reproductive Sciences Center.
How it works
The technique avoids damaging early stem cells, which are essential for long-term fertility. Instead, it intervenes later in the process, reducing the risk of permanent effects.
“Meiosis represents a natural checkpoint in sperm production where transient inhibition could achieve precise and reversible fertility control,” argue Cohen and colleagues.
The drug used in the study, known as JQ1, was originally designed for cancer treatment but has shown effectiveness in blocking sperm development at this stage.
Promising results
Tests in male mice showed that the treatment was effective and did not cause lasting harm. After stopping the drug, sperm production resumed within weeks.
Researchers also reported that two generations of offspring were born without abnormalities, suggesting the approach may be safe.
“Our study shows that mostly we recover normal meiosis and complete sperm function, and more importantly, that the offspring are completely normal,” Cohen says.
Looking ahead
Despite the encouraging findings, further testing is required before human trials can begin for this specific drug.
Other nonhormonal contraceptives, such as YCT-529, are already in phase 2 clinical trials and may reach the market sooner.
“Few reversible male contraceptives have advanced toward clinical translation,” the authors write.
“The development of reversible, nonhormonal male contraceptives remains a critical unmet need for achieving reproductive equity.”
Sources: ScienceAlert, Proceedings of the National Academy of Sciences
